- via Notable Calls
- Athersys' (NASDAQ:ATHX) MultiStem is a potentially revolutionary stroke treatment, says William Blair, initiating coverage with an $11 price target - this vs. today's close of $1.18.
- The team at Blair sees peak sales potential of $3.9B against the company's current market cap of just $133M.
- Shares +16.1% after hours to $1.37.
William Blair sees Athersys as nearly a 10-bagger; shares +16% in post-market
Recommended For You
About ATHXQ Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ATHXQ | - | - |
Athersys, Inc. |